Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06809114 · ClinicalTrials.gov registry record · Phase 1
FIH Study to Evaluate Safety, Tolerability, PK, PD & Preliminary Efficacy of AT03-65 With Advanced Solid Tumors
A Phase 1 study of Solid Tumor, sponsored by Axcynsis Therapeutics Pte.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 83
- Enrollment target
- 1
- Study location
NCT06809114: Recruiting Phase 1 study of Solid Tumor, sponsored by Axcynsis Therapeutics Pte.
NCT06809114 is a Phase 1 study of Solid Tumor that is actively recruiting participants, run by Axcynsis Therapeutics Pte. The registered enrollment target is 83 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (62% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06809114, a Phase 1 study of Solid Tumor, is actively recruiting participants, sponsored by Axcynsis Therapeutics Pte.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 83 participants
- Enrollment target
- 1
- Study location
Study Summary
A Phase I, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AT03-65 in Adults with Advanced Solid Tumors
Primary Outcome
The MTD is defined as the highest dose with an observed incidence of DLT in no more than one out of six patients treated at a particular dose level.
Conditions Studied
Interventions
- DRUG AT03-65
Study Locations (1)
Oregon
- Oregon Health & Science University (OHSU) - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2026-01-14 |
| Est. Completion | 2028-08 |
| Phase | Phase 1 |
What NCT06809114 shows while recruiting
NCT06809114 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 83 participants, a relatively small participant target, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (62% lower).
The record links to 1 condition, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which AT03-65 is the first listed.
NCT06809114 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT06809114 about?
NCT06809114 is a clinical study titled "FIH Study to Evaluate Safety, Tolerability, PK, PD & Preliminary Efficacy of AT03-65 With Advanced Solid Tumors". A Phase I, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AT03-65 in Adults with Advanced Solid Tumors
What is the current status of trial NCT06809114?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 83 participants. The study started on 2026-01-14. Estimated completion is 2028-08.
What conditions does trial NCT06809114 study?
This clinical trial studies the following conditions: Solid Tumor.
What interventions are being tested in trial NCT06809114?
The interventions under investigation include: AT03-65 (DRUG).
Who is sponsoring clinical trial NCT06809114?
This trial is sponsored by Axcynsis Therapeutics Pte, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06809114 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06809114's enrollment target sits among peer trials
83 97th of 196 higher than 100 of 196 other Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02974647 · 83 participants · Phase 2
Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
- NCT03919292 · 83 participants · Phase 1
Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca
- NCT04626674 · 83 participants · Phase 1
A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)
- NCT05277168 · 83 participants · Phase 1
A Trial TO Evaluate THE Safety, Tolerability, Pharmacokinetics, AND Efficacy OF Shr-a1904 IN Subjects With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI